Prognostic value of serum aldo-keto reductase family 1 member B10 in hepatocellular carcinoma

Table 1 The relationship between serum aldo-keto reductase family 1 member B10 levels and clinical pathological characteristics of hepatocellular carcinoma patients, n (%)

Item	AKR1B10 (pg/mL)		χ2	P value
	< 1584.97 (n = 27)	≥ 1584.97 (n = 75)
Gender			2.34	0.126
Male	19 (70.4)	63 (84.0)
Female	8 (29.6)	12 (16.0)
Age			0.026	0.872
< 65 years old	19 (70.4)	54 (72.0)
≥ 65 years old	8 (29.6)	21 (28.0)
Smoking history			1.137	0.286
Absent	14 (51.9)	30 (40.0)
Present	13 (48.1)	45 (60.0)
History of alcohol consumption			2.974	0.085
Absent	16 (59.3)	30 (40.0)
Present	11 (40.7)	45 (60.0)
Viral hepatitis				0.1701
Absent	2 (7.4)	1 (1.3)
Present	25 (92.60)	74 (98.7)
Hepatic cirrhosis			0.027	0.87
Absent	5 (18.5)	11 (14.70)
Present	22 (81.5)	64 (85.3)
Antiviral therapy			0.276	0.6
Absent	15 (55.6)	46 (61.3)
Present	12 (44.4)	29 (38.7)
Number of tumors			1.541	0.215
1	16 (59.3)	34 (45.3)
≥ 1	11 (40.7)	41 (54.7)
Tumor size (cm)			3.999	0.046
< 5	19 (70.4)	36 (48.0)
≥ 5	8 (29.6)	39 (52.0)
Portal vein tumor thrombus			2.447	0.118
Absent	22 (81.5)	49 (65.3)
Present	5 (18.5)	26 (34.7)
Vascular tumor thrombus			0.417	0.518
Absent	27 (100)	71 (94.7)
Present	0 (0)	4 (5.3)
Metastasis to lymph nodes or distant metastasis			0.018	0.893
Absent	24 (88.9)	64 (85.3)
Present	3 (11.1)	11 (14.7)
Ascites			3.902	0.048
Absent	25 (92.6)	56 (74.7)
Present	2 (7.4)	19 (25.3)
Combined type 2 diabetes mellitus			1.043	0.167
Absent	26 (96.3)	65 (86.7)
Present	1 (3.7)	10 (13.3)
Microvascular invasion			0.33	0.566
Absent	24 (88.9)	71 (94.7)
Present	3 (11.1)	4 (5.3)
Satellite lesions				0.4611
Absent	26 (96.3)	74 (98.7)
Present	1 (3.7)	1 (1.3)
BCLC staging			3.987	0.046
A + B	21 (77.8)	42 (56.0)
C + D	6 (22.2)	33 (44.0)
BMI index			1.159	0.282
< 25	21 (77.8)	50 (66.7)
≥ 25	6 (22.2)	25 (33.3)
AFP (ng/mL)			1.346	0.246
< 5.89	12 (44.4)	24 (32.0)
≥ 5.89	15 (55.6)	51 (68.0)
AFP (ng/mL)			1.852	0.174
< 20	16 (59.3)	33 (44.0)
≥ 20	11 (40.7)	42 (56.0)
AFP (ng/mL)			0.006	0.94
< 400	20 (74.1)	55 (73.3)
≥ 400	7 (25.9)	20 (26.7)
GLU (mmol/L)			0.512	0.474
3.9-6.1	22 (81.5)	56 (74.7)
≥ 6.1	5 (18.5)	19 (25.3)
PT (seconds)			1.773	0.183
9-13	22 (81.5)	51 (68.0)
≥ 13	5 (18.5)	24 (32.0)
ALT (U/L)			0.914	0.339
7-40	21 (77.8)	51 (68.0)
≥ 40	6 (22.2)	24 (32.0)
AST (U/L)			0.891	0.345
13-35	14 (51.9)	31 (41.3)
≥ 35	13 (48.1)	44 (58.7)
TBIL (umol/L)			1.701	0.192
≤ 21	20 (74.1)	45 (60.00)
≥ 21	7 (25.9)	30 (40.0)
ALB (g/L)			1.152	0.283
40-55	19 (70.4)	44 (58.7)
< 40	8 (29.6)	31 (41.3)

¹Indicates that the P-value was calculated by Fisher’s exact test.

BCLC: Barcelona Clinic Liver Cancer; BMI: Body mass index; AFP: Alpha-fetoprotein; GLU: Glucose; PT: Prothrombin time; ALT: Alanine aminotransferase; AST: Aspartate aminotransferase; TBIL: Total bilirubin; ALB: Albumin; AKR1B10: Aldo-keto reductase family 1 member B10.